SAN FRANCISCO — The next generation of anti-restenosis combination products are en route, although a number of observers at this year's Transcatheter Cardiovascular Therapeutics see even the most well-developed version of a bioresorbable stent (BRS) as needing several more years before they will get to market. (Medical Device Daily)

SAN FRANCISCO – Bioresorbable stents may seem like the latest thing, but according to a panel moderator speaking during a session at Transcatheter Cardiovascular Therapeutics (TCT), the effort to bring them from a concept to reality has a history spanning more than two decades.